Blog

  • Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Gwynne on 2016-01-04.

    To ask the Secretary of State for Health, if his Department will make representations to NHS England on its decision to delay the implementation of the positive national commissioning policy on microprocessor-controlled knees.

    Alistair Burt

    The commissioning of prosthetics is the responsibility of NHS England as a specialised service. The rehabilitation and re-ablement of patients is provided at a local level by specialised Multi-Disciplinary Teams which should be consultant led. The NHS Standard Contract for Complex Disability Equipment – Prosthetics, sets out how the specialist centres should operate and the required level of prosthetic services to be delivered.

    A revised policy proposal for the routine commissioning of microprocessor controlled knees was considered by NHS England’s expert Clinical Priorities Advisory Group which recommended its adoption for routine commissioning. The proposal was then considered by NHS England’s Specialised Commissioning Oversight Group at its meeting on 9 December where it was agreed that NHS England would support this service development as a possible call on its resources. However given the potential scale of investment and the need to consider its priority relative to other treatments which would also have a possible call on the specialised commissioning resources, it was decided that the policy should go forward for consideration as part of NHS England’s next annual prioritisation round in June 2016.

  • Maria Caulfield – 2016 Parliamentary Question to the Department of Health

    Maria Caulfield – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Maria Caulfield on 2016-01-04.

    To ask the Secretary of State for Health, what steps he is taking to improve one year cancer survival rates over the next five years.

    Jane Ellison

    The independent Cancer Taskforce’s five-year strategy for cancer, Achieving World-Class Cancer Outcomes, published in July 2015, recommends improvements across the cancer pathway with the aim of improving survival rates. NHS England has appointed Cally Palmer as NHS National Cancer Director. She will lead on the implementation of the strategy, as well as new cancer vanguards to redesign care and patient experience.

    She is currently setting up a new Cancer Transformation Board to lead the roll-out of the recommendations of the new strategy, and a Cancer Advisory Group, chaired by Dr Harpal Kumar, Chief Executive of Cancer Research UK, will oversee and scrutinise their work. Timeframes and phasing for implementation will be dependent on the final financial settlement reached as a result of the spending review.

    We announced in September 2015 that Health Education England (HEE) is developing a new national training programme for an additional 200 staff to get the skills and expertise to carry out endoscopies by 2018. The content of the next mandate from the Government to HEE is currently being determined.

    A commitment to whole-person care for patients, including those living with and beyond cancer, is embedded throughout the cancer taskforce report. In addition, the cancer vanguards have been established to explore new models of care, with a focus on delivering more person-centred care.

    Ensuring the National Health Service is able to support the availability and use of effective treatments and medicines for rare cancers is a key priority. Cancer 52, an organisation which specifically represents patients with rarer cancers, was represented on the independent Cancer Taskforce. The Taskforce’s report made many recommendations relevant to rarer cancers, focussing in particular on improving access to diagnostic testing, including fast, direct general practitioner access to key blood tests, and increasing patient access to the most advanced treatments.

  • Maria Caulfield – 2016 Parliamentary Question to the Department of Health

    Maria Caulfield – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Maria Caulfield on 2016-01-04.

    To ask the Secretary of State for Health, what steps he is taking to improve outcomes for people with rarer cancers.

    Jane Ellison

    The independent Cancer Taskforce’s five-year strategy for cancer, Achieving World-Class Cancer Outcomes, published in July 2015, recommends improvements across the cancer pathway with the aim of improving survival rates. NHS England has appointed Cally Palmer as NHS National Cancer Director. She will lead on the implementation of the strategy, as well as new cancer vanguards to redesign care and patient experience.

    She is currently setting up a new Cancer Transformation Board to lead the roll-out of the recommendations of the new strategy, and a Cancer Advisory Group, chaired by Dr Harpal Kumar, Chief Executive of Cancer Research UK, will oversee and scrutinise their work. Timeframes and phasing for implementation will be dependent on the final financial settlement reached as a result of the spending review.

    We announced in September 2015 that Health Education England (HEE) is developing a new national training programme for an additional 200 staff to get the skills and expertise to carry out endoscopies by 2018. The content of the next mandate from the Government to HEE is currently being determined.

    A commitment to whole-person care for patients, including those living with and beyond cancer, is embedded throughout the cancer taskforce report. In addition, the cancer vanguards have been established to explore new models of care, with a focus on delivering more person-centred care.

    Ensuring the National Health Service is able to support the availability and use of effective treatments and medicines for rare cancers is a key priority. Cancer 52, an organisation which specifically represents patients with rarer cancers, was represented on the independent Cancer Taskforce. The Taskforce’s report made many recommendations relevant to rarer cancers, focussing in particular on improving access to diagnostic testing, including fast, direct general practitioner access to key blood tests, and increasing patient access to the most advanced treatments.

  • Maria Caulfield – 2016 Parliamentary Question to the Department of Health

    Maria Caulfield – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Maria Caulfield on 2016-01-04.

    To ask the Secretary of State for Health, what steps the Government plans to take to support whole person care across the cancer pathway over the next 15 years.

    Jane Ellison

    The independent Cancer Taskforce’s five-year strategy for cancer, Achieving World-Class Cancer Outcomes, published in July 2015, recommends improvements across the cancer pathway with the aim of improving survival rates. NHS England has appointed Cally Palmer as NHS National Cancer Director. She will lead on the implementation of the strategy, as well as new cancer vanguards to redesign care and patient experience.

    She is currently setting up a new Cancer Transformation Board to lead the roll-out of the recommendations of the new strategy, and a Cancer Advisory Group, chaired by Dr Harpal Kumar, Chief Executive of Cancer Research UK, will oversee and scrutinise their work. Timeframes and phasing for implementation will be dependent on the final financial settlement reached as a result of the spending review.

    We announced in September 2015 that Health Education England (HEE) is developing a new national training programme for an additional 200 staff to get the skills and expertise to carry out endoscopies by 2018. The content of the next mandate from the Government to HEE is currently being determined.

    A commitment to whole-person care for patients, including those living with and beyond cancer, is embedded throughout the cancer taskforce report. In addition, the cancer vanguards have been established to explore new models of care, with a focus on delivering more person-centred care.

    Ensuring the National Health Service is able to support the availability and use of effective treatments and medicines for rare cancers is a key priority. Cancer 52, an organisation which specifically represents patients with rarer cancers, was represented on the independent Cancer Taskforce. The Taskforce’s report made many recommendations relevant to rarer cancers, focussing in particular on improving access to diagnostic testing, including fast, direct general practitioner access to key blood tests, and increasing patient access to the most advanced treatments.

  • Maria Caulfield – 2016 Parliamentary Question to the Department of Health

    Maria Caulfield – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Maria Caulfield on 2016-01-04.

    To ask the Secretary of State for Health, what discussions he has had with (a) NHS England and (b) Health Education England on the strategic review of the cancer workforce recommended in the report of the Independent Cancer Taskforce.

    Jane Ellison

    The independent Cancer Taskforce’s five-year strategy for cancer, Achieving World-Class Cancer Outcomes, published in July 2015, recommends improvements across the cancer pathway with the aim of improving survival rates. NHS England has appointed Cally Palmer as NHS National Cancer Director. She will lead on the implementation of the strategy, as well as new cancer vanguards to redesign care and patient experience.

    She is currently setting up a new Cancer Transformation Board to lead the roll-out of the recommendations of the new strategy, and a Cancer Advisory Group, chaired by Dr Harpal Kumar, Chief Executive of Cancer Research UK, will oversee and scrutinise their work. Timeframes and phasing for implementation will be dependent on the final financial settlement reached as a result of the spending review.

    We announced in September 2015 that Health Education England (HEE) is developing a new national training programme for an additional 200 staff to get the skills and expertise to carry out endoscopies by 2018. The content of the next mandate from the Government to HEE is currently being determined.

    A commitment to whole-person care for patients, including those living with and beyond cancer, is embedded throughout the cancer taskforce report. In addition, the cancer vanguards have been established to explore new models of care, with a focus on delivering more person-centred care.

    Ensuring the National Health Service is able to support the availability and use of effective treatments and medicines for rare cancers is a key priority. Cancer 52, an organisation which specifically represents patients with rarer cancers, was represented on the independent Cancer Taskforce. The Taskforce’s report made many recommendations relevant to rarer cancers, focussing in particular on improving access to diagnostic testing, including fast, direct general practitioner access to key blood tests, and increasing patient access to the most advanced treatments.

  • Maria Caulfield – 2016 Parliamentary Question to the Department of Health

    Maria Caulfield – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Maria Caulfield on 2016-01-04.

    To ask the Secretary of State for Health, what plans he has to respond to the report of the Independent Cancer Taskforce; and what the timetable is for implementation of the recommendations of that report.

    Jane Ellison

    The independent Cancer Taskforce’s five-year strategy for cancer, Achieving World-Class Cancer Outcomes, published in July 2015, recommends improvements across the cancer pathway with the aim of improving survival rates. NHS England has appointed Cally Palmer as NHS National Cancer Director. She will lead on the implementation of the strategy, as well as new cancer vanguards to redesign care and patient experience.

    She is currently setting up a new Cancer Transformation Board to lead the roll-out of the recommendations of the new strategy, and a Cancer Advisory Group, chaired by Dr Harpal Kumar, Chief Executive of Cancer Research UK, will oversee and scrutinise their work. Timeframes and phasing for implementation will be dependent on the final financial settlement reached as a result of the spending review.

    We announced in September 2015 that Health Education England (HEE) is developing a new national training programme for an additional 200 staff to get the skills and expertise to carry out endoscopies by 2018. The content of the next mandate from the Government to HEE is currently being determined.

    A commitment to whole-person care for patients, including those living with and beyond cancer, is embedded throughout the cancer taskforce report. In addition, the cancer vanguards have been established to explore new models of care, with a focus on delivering more person-centred care.

    Ensuring the National Health Service is able to support the availability and use of effective treatments and medicines for rare cancers is a key priority. Cancer 52, an organisation which specifically represents patients with rarer cancers, was represented on the independent Cancer Taskforce. The Taskforce’s report made many recommendations relevant to rarer cancers, focussing in particular on improving access to diagnostic testing, including fast, direct general practitioner access to key blood tests, and increasing patient access to the most advanced treatments.

  • Mark Tami – 2016 Parliamentary Question to the Department of Health

    Mark Tami – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Mark Tami on 2016-01-04.

    To ask the Secretary of State for Health, what steps he is taking to ensure that patients with multiple myeloma receive treatment at the highest standard of care comparable to other similar nations.

    Jane Ellison

    Ensuring that the National Health Service is able to support the availability and use of effective treatments and medicines for rare cancers, including multiple myeloma, is a key priority.

    Cancer 52, an organisation which specifically represents patients with rarer cancers, was represented on the independent Cancer Taskforce. In July 2015, the Taskforce published its report, Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020. It made many recommendations relevant to rarer and blood cancers, focussing in particular on improving access to diagnostic testing, including fast, direct general practitioner access to key blood tests, and increasing patient access to the most advanced treatments.

    NHS England has well established structures and processes which ensure that the best possible treatments are commissioned across England for cancer, including both blood and rare cancers. NHS England obtains clinical advice about current and new treatments and clinical guidelines predominantly through clinical reference groups.

    The National Institute for Health and Care Excellence is developing guidelines for the treatment of multiple myeloma and these are currently subject to public consultation.

    In addition, a multiple myeloma algorithm is in development, which will help clinicians and patients to prescribe the appropriate chemotherapy care at the optimum point of the care pathway.

  • Margaret Hodge – 2016 Parliamentary Question to the Department of Health

    Margaret Hodge – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Margaret Hodge on 2016-01-04.

    To ask the Secretary of State for Health, when the UK Genetics Testing Network plans to update its data on UK molecular genetic test activity rates.

    George Freeman

    The UK Genetic Testing Network has been working closely with the Health and Social Care Information Centre (HSCIC) and NHS England to re-establish the national data collection for molecular genetic test activity rates. They are in the final stages of implementing a HSCIC national dataset and collection process for United Kingdom data. Data collection is expected to have been completed by the summer of 2016 with a full update prepared by the end of the year.

  • Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Gwynne on 2016-01-04.

    To ask the Secretary of State for Health, if he will take steps to ensure that lower limb amputees are able to access microprocessor-controlled knees through the NHS via a specialised commissioning policy before June 2016.

    Alistair Burt

    The commissioning of prosthetics is the responsibility of NHS England as a specialised service. The rehabilitation and re-ablement of patients is provided at a local level by specialised Multi-Disciplinary Teams which should be consultant led. The NHS Standard Contract for Complex Disability Equipment – Prosthetics, sets out how the specialist centres should operate and the required level of prosthetic services to be delivered.

    A revised policy proposal for the routine commissioning of microprocessor controlled knees was considered by NHS England’s expert Clinical Priorities Advisory Group which recommended its adoption for routine commissioning. The proposal was then considered by NHS England’s Specialised Commissioning Oversight Group at its meeting on 9 December where it was agreed that NHS England would support this service development as a possible call on its resources. However given the potential scale of investment and the need to consider its priority relative to other treatments which would also have a possible call on the specialised commissioning resources, it was decided that the policy should go forward for consideration as part of NHS England’s next annual prioritisation round in June 2016.

  • Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Gwynne on 2016-01-04.

    To ask the Secretary of State for Health, what steps his Department is taking to ensure that all lower limb amputees have access to the most appropriate prosthetics.

    Alistair Burt

    The commissioning of prosthetics is the responsibility of NHS England as a specialised service. The rehabilitation and re-ablement of patients is provided at a local level by specialised Multi-Disciplinary Teams which should be consultant led. The NHS Standard Contract for Complex Disability Equipment – Prosthetics, sets out how the specialist centres should operate and the required level of prosthetic services to be delivered.

    A revised policy proposal for the routine commissioning of microprocessor controlled knees was considered by NHS England’s expert Clinical Priorities Advisory Group which recommended its adoption for routine commissioning. The proposal was then considered by NHS England’s Specialised Commissioning Oversight Group at its meeting on 9 December where it was agreed that NHS England would support this service development as a possible call on its resources. However given the potential scale of investment and the need to consider its priority relative to other treatments which would also have a possible call on the specialised commissioning resources, it was decided that the policy should go forward for consideration as part of NHS England’s next annual prioritisation round in June 2016.